Regular use of 
          ibuprofen may lower lung cancer risk among high-risk subgroups of 
          cigarette smokers
          Via 
          MARKETWIRE
          December 7, 2016
          VIENNA, Austria – 
          Regular use of ibuprofen may lower the risk of lung cancer among those 
          with a history of cigarette smoking, according to research presented 
          at the IASLC 17th World Conference on Lung Cancer (WCLC) in Vienna, 
          Austria.
          It has been established that 
          chronic inflammation appears to increase the risk of lung cancer, and 
          medicines that reduce inflammation have been shown to reduce this 
          risk. However, few prospective studies have examined associations 
          between lung cancer and non-steroidal anti-inflammatory drugs.
          To test whether a common 
          NSAID can reduce the risk of lung cancer, Dr. Marisa Bittoni and her 
          colleagues from The Ohio State University in Columbus, Ohio, examined 
          data from 10,735 participants in the Third National Health and 
          Nutrition Examination Survey, or NHANES III.
          Baseline data on smoking, 
          NSAIDs and other lifestyle variables were collected for 10,735 
          participants starting in 1988-1994, and cause-specific mortality 
          status was ascertained through probabilistic record matching using the 
          National Death Index through 2006. Cox proportional hazards regression 
          models were used to estimate hazard ratios (HRs) to quantify 
          associations between NSAID use and lung cancer death, with adjustment 
          for current smoking and other variables.
          Over 18 years of follow-up, 
          269 individuals died from lung cancer, of which 252 (93.6 percent) 
          reported a history of cigarette smoking. Since all but 17 of the 269 
          fatal lung cancer cases occurred among current or former smokers, 
          estimates of NSAID effects were ascertained from a sub-cohort of 5,882 
          individuals who reported a history of past or current cigarette 
          smoking.
          Bittoni found that 
          prospective data from NHANES III showed that among adults with a 
          history of past or current smoking, ibuprofen intake was associated 
          with a substantial (48 percent) reduction in the risk of dying from 
          lung cancer. Effects of aspirin and acetaminophen were not 
          statistically significant.
          "These results suggest that 
          regular use of certain NSAIDs may be beneficial for high-risk 
          subgroups of smokers as a lung cancer prevention strategy," Bittoni 
          said.
          The IASLC 17th WCLC is the 
          world's largest meeting dedicated to lung cancer and other thoracic 
          malignancies, attracting more than 6,000 researchers, physicians, and 
          specialists from more than 100 countries. For more information on the 
          IASLC 17th WCLC, visit: http://wclc2016.iaslc.org/.